Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy
Author:
Funder
Breast Cancer Research Foundation
Publisher
Elsevier BV
Subject
Oncology,Hematology
Link
http://academic.oup.com/annonc/article-pdf/30/2/236/27970093/mdy547.pdf
Reference14 articles.
1. Adjuvant capecitabine for breast cancer after preoperative chemotherapy;Masuda;N Engl J Med,2017
2. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis;Cortazar;Lancet,2014
3. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy;Symmans;JCO,2007
4. Long-term prognostic risk after neoadjuvant chemotherapy associated with residual cancer burden and breast cancer subtype;Symmans;JCO,2017
5. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy;Denkert;Lancet Oncol,2018
Cited by 119 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Multiplexed high-throughput immune cell imaging in patients with high-risk triple negative early breast cancer: Analysis from the International Breast Cancer Study Group (IBCSG) Trial 22-00;European Journal of Cancer;2024-03
2. Pathological response and tumor stroma immunogenic features predict long-term survival in non-small cell lung cancer after neoadjuvant chemotherapy;Cellular Oncology;2024-02-06
3. Neoadjuvant therapy in hormone Receptor-Positive/HER2-Negative breast cancer;Cancer Treatment Reviews;2024-02
4. High tumor infiltrating lymphocytes are significantly associated with pathological complete response in triple negative breast cancer treated with neoadjuvant KEYNOTE-522 chemoimmunotherapy;Breast Cancer Research and Treatment;2024-01-30
5. The residual cancer burden index as a valid prognostic indicator in breast cancer after neoadjuvant chemotherapy;BMC Cancer;2024-01-02
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3